Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01938833|
Recruitment Status : Terminated (Closed by Sponsor)
First Posted : September 10, 2013
Results First Posted : September 29, 2017
Last Update Posted : December 28, 2017
|Condition or disease||Intervention/treatment||Phase|
|HER2-negative Breast Cancer Inflammatory Breast Cancer Male Breast Cancer Recurrent Breast Cancer Stage IV Breast Cancer||Drug: Romidepsin Drug: Abraxane||Phase 1 Phase 2|
- To assess the safety of the combination of romidepsin plus Abraxane (paclitaxel albumin-stabilized nanoparticle formulation) delivered weekly. (Phase I)
- To determine the maximum tolerated dose (MTD) of romidepsin with full dose weekly Abraxane to define a recommended phase II doses of the combination. (Phase I)
- To assess the progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2) negative, newly diagnosed metastatic inflammatory breast cancer treated with the combination of romidepsin and Abraxane. (Phase II)
- To assess the safety and tolerability of the combination of romidepsin and Abraxane.
- To determine the adverse event profile of the combination of romidepsin and Abraxane.
- To assess the overall response rate (ORR) and clinical benefit rate (CBR) in patients with newly recurrent inflammatory breast cancer (IBC) treated with the combination of romidepsin and Abraxane.
OUTLINE: This is a phase I, dose-escalation study of romidepsin followed by a phase II study.
Patients receive paclitaxel albumin-stabilized nanoparticle formulation intravenously (IV) over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually thereafter.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||9 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer|
|Actual Study Start Date :||April 2014|
|Actual Primary Completion Date :||August 18, 2016|
|Actual Study Completion Date :||December 8, 2016|
Experimental: Treatment (Romidepsin and Abraxane)
Patients receive abraxane IV over 30 minutes and romidepsin IV over 60 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- Maximum-Tolerated Dose of Romidepsin (Phase I) [ Time Frame: 28 days ]Determined according to incidence of dose-limiting toxicity, graded using the National Cancer Institute (NCI) CTCAE version 4.0
- Progression-Free Survival (PFS) [ Time Frame: The duration of time from start of treatment to time of progression or death, whichever occurs first, assessed up to 5 years ]
- Incidence of Adverse Events, Graded According to NCI CTCAE Version 4.0 [ Time Frame: Up to 30 days ]Summary tables of grade 2, 3, and 4 toxicities, adverse events (AE), and serious adverse events (SAE) will be generated at the conclusion of the study as well as at the conclusion of phase I study and after 15 patients have been collected on at the interim evaluation time point of the phase 2 part of the study.
- Overall Response Rate (ORR) [ Time Frame: Up to 5 years ]The 95% confidence intervals should be provided.
- Clinical Benefit Rate (CBR) [ Time Frame: Up to 5 years ]The 95% confidence intervals should be provided.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01938833
|United States, Pennsylvania|
|Thomas Jefferson University|
|Philadelphia, Pennsylvania, United States, 19107|
|Principal Investigator:||Maysa Abu-khalaf, MD||Thomas Jefferson University|